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It is unclear whether mutations in fused in sarcoma (FUS) cause familial amyotrophic lateral sclerosis via a
loss-of-function effect due to titrating FUS from the nucleus or a gain-of-function effect from cytoplasmic
overabundance. To investigate this question, we generated a series of independent Caenorhabditis elegans
lines expressing mutant or wild-type (WT) human FUS. We show that mutant FUS, but not WT-FUS, causes
cytoplasmic mislocalization associated with progressive motor dysfunction and reduced lifespan. The sever-
ity of the mutant phenotype in C. elegans was directly correlated with the severity of the illness caused by the
same mutation in humans, arguing that this model closely replicates key features of the human illness.
Importantly, the mutant phenotype could not be rescued by overexpression of WT-FUS, even though WT-
FUS had physiological intracellular localization, and was not recruited to the cytoplasmic mutant FUS aggre-
gates. Our data suggest that FUS mutants cause neuronal dysfunction by a dominant gain-of-function effect
related either to neurotoxic aggregates of mutant FUS in the cytoplasm or to dysfunction in its RNA-binding
functions.
INTRODUCTION
Mutations in the fused in sarcoma (FUS; ALS6) genes (1–3)
cause familial forms of amyotrophic lateral sclerosis (ALS),
and FUS may contribute to sporadic cases of frontotemporal
lobar degeneration (FTLD). FUS encodes an RNA-binding
protein that, under physiological conditions, is almost exclu-
sively expressed in the nucleus (4–6). However, in patients
with pathogenic FUS mutations and in patients with sporadic
forms of FTLD-FUS, the FUS protein accumulates in the cyto-
plasm of neurons in the spinal cord and brain (7–10). The ma-
jority of mutations occur in the C-terminus of the FUS protein,
which is thought to contain a nuclear targeting signal (11).
This has led to the conclusion that mislocalization of mutant
FUS causes either a loss-of-function effect (because of titra-
tion of FUS from the nucleus) or a gain-of-function effect
(arising from aberrant accumulation of FUS in the cytoplasm)
(12,13). The fact that mutations in the Tar DNA-binding
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protein 43 (TDP-43), another RNA-binding protein, also cause
familial ALS has led to the hypothesis that FUS and TDP-43
might work by the same mechanism (13). To further explore
the mechanism by which mutant FUS protein causes ALS,
we chose to create transgenic models bearing wild-type
(WT) or mutant human FUS in Caenorhabditis elegans. We
chose this model for three reasons. First, C. elegans has an
orthologue of human FUS, encouraging the notion that
models built in this animal would have biological validity.
Secondly, the genetics of C. elegans provides a powerful
tool to seek upstream and downstream partners via enhancer
and suppressor screens. Thirdly, the optical transparency of
C. elegans allows the application of biophysical techniques
to monitor the distribution and folding state of proteins of
interest (14).
RESULTS
A series of WT and mutant human FUS transgenes were gen-
erated and were then expressed in C. elegans under the control
of a pan-neuronal promoter (Fig. 1). These transgenes
included: (i) full-length (FL) WT human FUS (WT-FUS);
(ii) four different missense mutations associated with
varying clinical severity (as defined by age at onset and by
disease duration) of human ALS (R514G and R521G ¼
mild; R522G ¼ moderate and P525L ¼ severe) (1–3) (Sup-
plementary Material, Table S1) and (iii) two different
C-terminal-truncated FUS constructs (FUS513 and
FUS501—lacking the C-terminal 13 and 25 amino acids of
FUS, respectively). While the C-terminal-truncated constructs
are artificial, they are very similar to several human C-terminal
splicing/frame-shifting truncation mutations that are also asso-
ciated with severe ALS phenotypes (15,16). Each construct
was cloned into a vector containing a C. elegans pan-neuronal
promoter Prgef-1and an in-frame green fluorescent protein
(GFP S65T) or red fluorescent protein (TagRFP) at the N-
terminus. Multiple stable integrated transgenic FUS lines
were obtained for each mutant and WT-FUS construct. The
levels of FUS mRNA were determined for each line by quan-
titative reverse transcriptase–polymerase chain reaction
(qRT–PCR), and transgenic lines with similar levels of ex-
pression (1.00–1.78-fold of WT-FUS) were chosen for subse-
quent experiments (Supplementary Material, Fig. S1).
Mutations in FUS cause its accumulation in cytoplasmic
inclusions
Transgenic animals expressing only GFP under the control of
the same pan-neuronal Prgef-1 promoter showed diffuse
nuclear and cytoplasmic signals in neurons (data not shown).
In contrast, the GFP-tagged FL WT-FUS was detected only
in the nuclei of neurons (nuclear FUS/total FUS ratio ¼
93+ 3%, n ¼ 20 animals per transgenic strain) (Figs 2A and
B and 3A). The nuclear localization of WT-FUS is consistent
with the physiological subcellular localization of FUS in
healthy human neurons (1,2). Immunostaining with anti-FUS
antibody revealed that the FUS immunoreactivity fully repli-
cated the subcellular distribution of the GFP signal in the
same animals, indicating that the GFP tag was a reliable indi-
cator of FUS localization in vivo (Supplementary Material,
Fig. S2).
In animals expressing R514G and R521G mutations, which
have a mild ALS phenotype in human ALS cases (1), the
pattern of GFP-FUS was identical to WT-FUS at all ages
(nuclear FUS/total FUS ratio ¼ 92+ 3 and 96+ 3%, respect-
ively) (Figs 2A and B and 3A). In animals expressing the
R522G mutation, which has a moderate human ALS pheno-
type (1), FUS was also present in the nuclei of neurons, but
there was some FUS diffusely present in the cytoplasm
(nuclear FUS/total FUS ratio ¼ 59+ 10%, P, 0.001 com-
pared with WT-FUS) (Figs 2A and B and 3A). In animals
expressing the clinically severe P525L mutation, nearly half
of the total neuronal FUS was located in the cytoplasm in
an uneven, clumpy distribution (nuclear FUS/total FUS
ratio ¼ 52+ 9%, P , 0.001 compared with WT-FUS)
(Figs 2A and B and 3A). Both truncated FUS constructs
also showed strong, clumpy, cytoplasmic FUS with less
nuclear FUS (nuclear FUS/total FUS ratio ¼ 44+ 4 and
43+ 5% for FUS513 and FUS501, respectively) (Figs 2A
and B and 3A).
Mutant FUS accumulates and aggregates in neuronal
cytoplasm in vivo
To determine whether the cytoplasmic inclusions contained in-
soluble aggregates of FUS, we undertook sequential extraction
of animals with RIPA and then with urea buffer. This analysis
revealed that there were increased steady-state levels of FUS
Figure 1. Transgene constructs. WT FL FUS, FUS with five different clinical mutations (R514G, R521G, R522G, R524S and P525L) and two truncated FUS
(FUS513 and FUS501) were generated and injected into C. elegans. GFP, green fluorescent protein; QGSY-rich, glutamine–glycine–serine–tyrosine-rich
region; G-rich, glycine-rich region; RRM, RNA recognition motif; RGG-rich, arginine–glycine–glycine-rich region.
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in animals that had cytoplasmic FUS accumulation (Fig. 3B)
and that some of this accumulated protein was in the form
of sodium dodecyl sulphate-insoluble, urea-soluble aggregates
(Fig. 3C). All animals had similar levels of transgene mRNA
expression, and there was no correlation between the level of
transgene expression and the abundance of FUS (Supplemen-
tary Material, Fig. S1). The differences in steady-state levels
of FUS protein, therefore, likely reflect differences in the
amount of cytoplasmic aggregated FUS, which in turn could
reflect differences in the intrinsic aggregation propensity of
the various mutant FUS proteins.
Animals with FUS aggregates show progressive motor
defects and die prematurely
To determine whether the cytoplasmic aggregation of FUS
was accompanied by functional deficits, we assessed the
motor activity of the transgenic animals by employing a stand-
ard thrashing assay (http://www.wormbook.org/chapters/
www_behavior/behavior.html#sec7). This assay measured
motor activity by counting the frequency of body bends
when animals were placed in liquid M9 buffer. At 3 days of
age (i.e. young adults), animals expressing only a GFP trans-
gene had a slight motor disturbance (100.7+ 5.6/min) com-
pared with non-transgenic N2 animals of the same age (n ¼
20, 115.7+ 6.3/min, P , 0.05, Fig. 3D). Animals expressing
WT-FUS had a similar minor impairment of motor function
(104.8+ 5.0/min), indicating that expression of WT-FUS
per se has little or no toxicity. The motor function of
animals expressing the clinically mild R514G and R521G
mutations, which had predominantly nuclear FUS, was indis-
tinguishable from that of WT-FUS and GFP-only animals
(R514G 103.5+ 6.0/min and R521G ¼ 103.8+ 5.9/min). In
contrast, animals expressing either the moderate R522G
(96.3+ 4.9/min) or the severe P525L mutation (91.8+ 5.2/
min) showed significantly impaired motor function compared
with WT-FUS (P, 0.05 and P, 0.001, respectively).
Animals expressing C-terminal-truncated FUS513 (69.7+
8.9/min) or FUS501 (54.6+ 8.7/min) also had significantly
impaired motor function compared with WT-FUS (P ,
0.001). Representative locomotor behaviours of the animals
are shown in Supplementary Material, Movies SM1–SM5.
Because human FUS mutations differ both in their age of
onset and rates of progression, we next assessed rates of progres-
sion by comparing motor performance of 3-day-old and
6-day-old adult animals (n ¼ 20 for each strain). The
6-day-old non-transgenic WT (N2), WT-FUS, R514G and
R521G animals showed minor degrees of age-related decline
compared with the 3-day-old N2 animals (211.0+ 0.8,
29.2+ 1.3, 210.8+ 1.7 and 27.5+ 1.4%, respectively;
P ¼ NS) (Fig. 3E and F). However, the decline in R522G,
P525L, FUS513 and FUS501 animals (219.1+ 1.6,
225.3+ 1.3, 227.7+ 1.8 and 222.3+ 2.1%, respectively)
was significantly greater than that in N2 and WT-FUS animals
(P , 0.001). These differences in rates of progression in
mutant FUS animals closely parallel the differences in rates of
progression of ALS in humans with the same FUS mutations.
As is the case with human ALS, this progressive motor
paralysis was also accompanied by accelerated mortality. At
3 days of adult age, all transgenic animals appeared morpho-
logically similar to non-transgenic N2 animals and were not
distinguishable in size (Fig. 4A). However, at about 6 days
of age, P525L, FUS513 and FUS501 animals became
smaller compared with WT-FUS animals of the same age.
By 8 days of age, most of the P525L, FUS513 and FUS501
animals were partially or completely paralysed, severely
shrunken and many were dead (Fig. 4A). Kaplan–Meier
Figure 2. Representative images of transgenic FUS worms. (A) Live fluores-
cent images of neurons in the head and body and (B) confocal microscopic
images of immunostained animals. Non-transgenic N2 animals show no fluor-
escent signals with either wide-field (A) or confocal (B) microscope. GFP
signals are observed almost exclusively in the nuclei in WT-FUS (WT),
R514G and R521G (A, arrow). GFP signals in WT and R514G and DAPI per-
fectly overlap, suggesting that FUS in these two strains is exclusively
expressed in the nucleus (B, WT, arrow). R522G animals show both nuclear
(A and B, R522G, arrow) and cytoplasmic FUS (A and B, arrowhead), but
nuclear signal is still stronger (A and B). P525L, FUS513 and FUS501
animals show marked cytoplasmic GFP signals (A and B, arrowheads),
which are rather stronger than those in nuclei (A and B, arrows). Staining pat-
terns with anti-GFP and anti-FUS antibodies are almost the same (B; Supple-
mentary Material, Fig. S2). There is no difference in the distribution of
GFP-positive neurons in each line. Scale bars: 20 mm (A) and 2.0 mm (B).
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analyses (n ¼ 20 animals/transgenic strain) revealed that
under our culture conditions, the mean lifespans of animals
expressing WT-FUS or the mild ALS mutations (R514G and
R521G) were not different from those of N2 animals
(Fig. 4B and C). In contrast, the mean lifespans of animals
expressing the R522G, P525L, FUS513 and FUS501 mutants
were reduced to 9.7+ 0.4, 9.3+ 0.3, 8.9+ 0.3 and 8.1+
0.2 days, respectively, and were significantly shorter than
Figure 3. Features of transgenic worms. (A) Ratio of nuclear FUS in each transgenic strain. In WT-FUS animals (WT), 93+3% of FUS is in the nucleus.
Nuclear FUS in R514G and R521G do not differ from that in WT (92+3 and 96+3%, respectively). However, R522G and P525L show significantly
lower ratio than WT (59+10 and 52+9%, respectively). FUS513 and FUS501 show even lower scores (44+4 and 43+5% of WT, respectively). NS,
not significant. ∗P, 0.05 and ∗∗∗P , 0.001. (B and C) Immunoblot analyses of FUS aggregation. (B) Whole lysates (80 mg) probed with anti-FUS or
anti-GFP antibodies. a-Tubulin was used as a loading control. (C) RIPA-soluble and RIPA-insoluble/urea soluble fractions from the whole lysates were separated
by sequential extraction and probed with anti-FUS antibody. (D–F) Thrashing assays. (D) Motor activity as measured by the thrashing assay at 3 days of age.
WT-FUS animals (WT) show slightly lower score than non-transgenic N2 animals (P, 0.05). Compared with WT, there is no decrease in R514G and R521G,
but R522G and P525L animals show significantly lower score by 8.2+4.6 and 12.5+5.0%, respectively (P, 0.05 for R521G and P , 0.001 for P525L). All
truncated strains (FUS513 and FUS501) show marked decrease by 33.5+8.5 and 45.2+4.0% of WT (P , 0.001). (E) Motor activity, as measured by thrash-
ing scores for 3-day-old and 6-day-old animals, shows age-related reductions in motor activity in all strains (11.9+3.7% decrease in movement activity) in N2
non-transgenic animals. The extents of decline in movement activity in WT-FUS, R514G and R521G animals were not different from that of N2 animals.
However, all of the other FUS mutants, including those associated with moderate and severe ALS phenotypes in humans (R522G, P525L, FUS513 and
FUS501), show significantly larger decreases at 6 days of age (P , 0.001). NS, not significant. ∗P , 0.05 and ∗∗∗P , 0.001. (F) The rate of progression of
motor impairment normalized to the activity at day 3 shows that the R522L (moderate), R525L, FUS 513 and FUS501 (severe) animals have greater rates
of progression in proportion to the severity of the human ALS phenotypes associated with those mutants.
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those of non-transgenic N2 (12.8+ 0.3 days, P , 0.001) and
WT-FUS animals (12.1+ 0.4 days, P, 0.001). Neurons
from 6–8-day-old R522G, P525L, FUS513 and FUS501
animals also had abundant FUS-positive granules in the cyto-
plasm that were not present at younger ages (Fig. 4D).
Cellular stress exacerbates both cytoplasmic
mislocalization of FUS and motor dysfunction
Because heat stress has been previously shown to cause mis-
localization of FUS, we applied brief periods of thermal
stress (358C for 30 min) and then monitored both the subcel-
lular distribution of FUS and the severity of motor dysfunc-
tion. Because FUS is an RNA-binding protein, we were
particularly interested to determine whether it might
co-localize with cytoplasmic stress granules, which can be
monitored by poly (A)-binding protein (PAB-1) (17). At all
ages, animals over-expressing PAB-1 tagged at the N-terminus
with mCherry showed only diffuse cytoplasmic fluorescent
signals with no apparent stress granules under normal condi-
tions (Fig. 5A, no HS). However, 30 min after application of
358C heat shock, PAB-1 coalesced into numerous cytoplasmic
granules (Fig. 5A). These PAB-1-positive stress granules
slowly disappeared, and PAB-1 staining reverted to the basal
diffuse cytoplasmic distribution by 6 h after heat shock
(Fig. 5A).
When PAB-1 was co-expressed with either WT-FUS or
mutant FUS, a small amount of PAB-1-positive stress granules
was observed under basal conditions (Fig. 5B). In the double
transgenic animals expressing WT or mutant FUS and
PAB-1, under the same basal conditions, the distribution and
morphology of FUS were identical to those in single transgen-
ic FUS animals, indicating that PAB-1 does not affect local-
ization of either WT-FUS or mutant FUS animals per se.
Figure 4. Age-dependent changes of FUS-expressing C. elegans. (A) Representative microscopic images of transgenic FUS animals. At 3 days of age, all trans-
genic lines look similar in size, whereas at 6 days of age, P525L and FUS501 animals are slightly shrunk compared with WT-FUS animals. At 8 days of age,
P525L and FUS501 animals are obviously smaller and pale. Scale bar: 0.2 mm for all images. (B) Kaplan–Meier survival curve and (C) lifespans. (B) WT-FUS
(WT), R514G and R521G animals live up to around 14 days, but most R522G, P525L, FUS513 and FUS501 animals died by 11 days. (C) The lifespans of WT,
R514G and R521G animals are not different for N2 animals, but lifespans of R522G, P525L, FUS513 and FUS501 are significantly shorter than those of both N2
and WT-FUS animals. NS, not significant; ∗∗∗P , 0.001. (D) Fluorescent microscopic images of FUS aggregates in transgenic FUS animals. At 8 days of age
(9 days for R522G), R522G, P525L, FUS513 and FUS501 animals show abundant FUS granules in the cytoplasm (arrows), which are not obvious in younger
animals (3-day-old). Scale bar: 2.0 mm.
Human Molecular Genetics, 2012, Vol. 21, No. 1 5
Following the heat shock, WT-FUS animals exhibited a small
increment in the number of stress granules in the cytoplasm,
but there was no corresponding cytoplasmic accumulation of
FUS (Fig. 5B). In sharp contrast, when the same heat shock
stimulus was applied to the R522G, P525L or FUS501
animals, all three mutant FUS lines showed more stress gran-
ules and obvious recruitment of the mutant FUS to the
heat-stress-induced granules.
Concomitantly, we assessed motor function in these trans-
genic animals. All animals showed impaired motility immedi-
ately after the heat shock. However, animals expressing
WT-FUS and animals expressing the very mild ALS mutants
(R514G and R521G) all rapidly recovered to baseline motor
function within 30 min. In sharp contrast, all of the transgenic
animals expressing the moderate and severe ALS mutants that
cause cytoplasmic aggregates of FUS showed persistent motor
deficits at 30 min after the heat shock (Fig. 5C, P , 0.001,
compared with WT-FUS animals). Other assays of neuronal
activity, such as escaping behaviour following body touch,
also showed a persistent post-heat-shock motor defect in the
animals with persistent cytoplasmic FUS (Supplementary
Material, Fig. S3). These results support the notion that
cytoplasmic accumulation of FUS is neurotoxic, but does
not exclude the possibility that mutant FUS binds WT-FUS
and titrates it from the nucleus.
WT-FUS does not rescue mutant FUS and is not recruited
to mutant FUS aggregates
To test the hypothesis that mutant FUS might remove
WT-FUS from the nucleus, and thereby cause a
loss-of-function effect, we generated transgenic animals
expressing WT-FUS labelled with TagRFP (TagRFP-WT-
FUS) under the same pan-neuronal promoter. TagRFP-WT-
FUS, like the previously described GFP-WT-FUS, was
expressed in the nucleus, but was not recruited onto stress
granules following heat shock and was not associated with sig-
nificant neurological deficits (Fig. 6A and B, n ¼ 10 each). In
sharp contrast, the double transgenic animals (TagRFP-
WT-FUS and GFP-FUS-P525L) showed the presence of
TagRFP-WT-FUS in the nucleus and GFP-FUS-P525L in
the nucleus and cytoplasm under basal conditions (Fig. 6A).
Following heat shock, significant quantities of GFP-FUS-
P525L were recruited to stress granules, but the TagRFP-
Figure 5. Effects of heat shock on transgenic FUS animals. (A) PAB-1 expression and (B) effect of heat shock. Under basal conditions, PAB-1 is diffusely
expressed in cytoplasm (A, no HS, arrow). Thirty minutes after heat shock, neurons developed some stress granules in the cytoplasm (A, 30 min, arrowheads),
but most of them disappear 6 h after heat shock (A, 6 h). (B) Transgenic animals after single heat shock. There are more stress granules in WT-FUS (WT)
animals after heat shock, but still FUS remains in the nucleolus [(B), WT/HS(+), arrowheads]. In contrast, R522G, P525L and FUS501 animals show many
granules that are both FUS- and PAB-1-positive [R522G/HS(+), P525L/HS(+) and FUS501/HS(+), open arrowheads]. Scale bar: 2.0 mm. (C) Thrashing
assay of transgenic animals with and without heat shock. WT-FUS (WT), R514G and R521G animals show no significant decrease after recovery from the
heat shock, but all other strains (R522G, P525L, FUS513 and FUS501) show significantly decreased motor activity after heat shock. NS, not significant;
∗∗∗P , 0.001.
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WT-FUS remained in the nucleus (Fig. 6A). Importantly, these
double transgenic animals and the single transgenic
GFP-FUS-P525L animals had equivalent degrees of impaired
motor activity and equivalent degrees of sensitivity to heat
stress (Fig. 6B). Mutant FUS is therefore likely to cause
ALS through a dominant gain-of-function effect, instead of a
loss-of-function effect through titrating and reducing the
WT-FUS function.
DISCUSSION
The experiments reported here demonstrate that pathogenic
missense mutations in FUS that cause ALS in humans also
cause neuronal dysfunction and death of C. elegans expressing
these same mutant proteins. Importantly, there are strong par-
allels in the genotype-to-phenotype correlations between the
human disease and the phenotypes in C. elegans described
here. These similarities strongly argue that the mutant
human proteins, when expressed in C. elegans, are closely
modelling a fundamental property of these mutations in
humans.
Our data indicate that ALS-associated mutations in FUS
likely cause neurodegeneration via a toxic gain-of-function
effect that is likely to be a consequence of the accumulation
of FUS in the cytoplasm, rather than titration of FUS from
its physiological location in the nucleus. This toxic
gain-of-function effect could be mediated by either of two
mechanisms. First, as is widely held in the field, it is conceiv-
able that this toxic effect could be attributable to changes in
RNA metabolism induced by the mutant FUS. Secondly, it
is also possible that the aggregated FUS itself is the neurotoxic
moiety, as is the case for several other neurotoxic intracellular
and extracellular protein aggregates (e.g. tau, alpha-synuclein
and huntingtin). Under such circumstances, the mutant,
aggregation-prone forms may have a novel function unrelated
or only partly related to the native function. Such is the case
with ALS-inducing mutations in SOD1, which do not appear
to work via alterations in superoxide dismutase activity (18).
The animal models described here will be of use in the neces-
sary work that will be required to discriminate these two pos-
sibilities. Additional work will also be required to understand
the functional significance of binding of mutant FUS to stress
granules, which have a role in cell viability and recovery after
stress (11,19,20).
MATERIALS AND METHODS
Transgenic FUS worms
Animals were maintained on nematode growth medium
(NGM) plates (1.8% agar, 0.3% NaCl, 0.25% peptone,
25 mM KPO4, 1 mM MgSO4, 1 mM CaCl2 and 5 mg/ml choles-
terol) at 228C. FL human FUS/TLS cDNA (NM_004960)
(WT-FUS) was mutated to contain either one of the five clin-
ical mutations (R514G, R521G, R522G, R524S and P525L).
Two C-terminal-truncated FUS constructs were generated
(FUS513 and FUS501), lacking the C-terminal 13 and 25
amino acids of FUS, respectively. Each construct was injected
together with lin-15 rescuing plasmid into a host worm with
temperature-sensitive lin-15 (n765) allele, and non-Muv
(multivulva) animals were selected for further analysis (21).
These transgenes were integrated into the genome to generate
stable transgenic lines by UV irradiation, and the lines were
outcrossed more than six times with N2 WT strain. Constructs
used in this study are summarized in Figure 1.
Poly (A)-binding protein (PAB-1) was used as a marker for
stress granules (17). PAB-1 was cloned into the pJH897 vector
with the tag replaced with mCherry at the N-terminus and was
injected, solely or together with FUS constructs, along with
the lin-15 rescuing plasmid into lin-15 worms. The N2 strain
and transgenic animals expressing only GFP (GFP-only
animals) were used as negative controls.
Quantitative RT–PCR
Transgene expression in each integrated strain was determined
using quantitative real-time PCR. Total RNA was prepared
from L4 stage animals with TRIzol reagent (Invitrogen) and
RNeasy kit (Qiagen, USA), according to the manufacturer’s’
Figure 6. Localization of WT-FUS in animals expressing mutant FUS. (A)
Representative fluorescence microscopic images of TagRFP-WT-FUS and
GFP-FUS P525L double transgenic animals with or without heat shock. The
distribution of TagRFP-WT-FUS and GFP-FUS P525L proteins was not
changed in double transgenic animals. After heat shock, GFP-FUS P525L
protein formed numerous cytoplasmic granules (arrows), whereas
TagRFP-WT-FUS remained in the nucleus. (B) Thrashing assay of the
single and double transgenic animals. Co-expression of WT-FUS did not
rescue motor activity impairment of double transgenic animals under basal
conditions. After heat shock, WT-FUS animals recovered within 30 min,
whereas both the single GFP-FUS P525L and double transgenic animals
showed persistent motor impairment. NS, not significant; ∗∗∗P , 0.001.
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instructions. cDNA was synthesized with AffinityScript
reverse transcriptase (Stratagene, USA) and was amplified
with primers: forward, 5′-TAAATTTGGTGGCCCTCGGG-3′
and reverse, 5′-TCACCCAGGCCTTGCACAAA-3′. The
amplification was monitored using SYBR Green Premix Ex
Taq reagent (Takara Bio, Japan) in ABI PRISM 7500 Real-
Time PCR System (Applied Biosystems, USA) with gpd-2
as an internal control.
Immunohistochemistry
FUS localization in neurons was assessed by fixation of the
animals with 4% paraformaldehyde in MRWB buffer
(80 mM KCl, 20 mM NaCl, 10 mM EGTA, 5 mM spermidine
HCl, 15 mM Na PIPES and 25% methanol, pH 7.4), reduction
with 1% 2-mercaptoethanol in BO3 buffer (25 mM H2BO3 and
125 mM NaOH), then oxidation in 0.3% H2O2/BO3 buffer and
incubation with primary antibody [monoclonal anti-GFP anti-
body (Invitrogen, 1:200 dilution) or rabbit polyclonal
anti-FUS antibody (Abcam, 1:200 dilution)] overnight at
room temperature. After several washes, the animals were
incubated with secondary antibody (1:400 dilution), washed
again and then mounted in DAPI to stain nuclei (Molecular
Probes, USA).
Nuclear FUS quantification
To quantify the ratio of nuclear to cytoplasmic FUS, fluores-
cent microscopic images of neurons in the body were used,
so that signals from other nearby neurons were not counted.
Using Image J, the nucleus and cytoplasm of the neuron
were cropped and the pixels were counted (3-day-old
animals, n ¼ 20 animals, 10 neurons from each). Pixels that
overlapped with DAPI were considered to be nuclear, and
pixels that did not were considered to be cytoplasmic.
Thrashing assay
Animals from each transgenic line were picked at L4 stage
(n ¼ 20). Sixteen hours later, the 3-day-old young adult
animals were transferred into 5 ml of M9 buffer (0.6%
Na2PO4, 0.3% KH2PO4, 0.5% NaCl and 0.01% NH4Cl) on a
glass slide. Thirty seconds after the transfer, the frequency
of the body bending was counted for 1 min (22). The same
protocol was used to assess the motor function in 6-day-old
adults.
Heat shock treatment
Animals were picked at L4 stage (n ¼ 16) and kept at 228C.
Sixteen hours later, the animals were subjected to heat shock
by incubation at 358C for 30 min. After heat shock, the
animals were returned to the 228C incubator for recovery
and were then assessed for functional deficits at 30 min after
heat shock.
Fluorescence microscopy
Transgenic FUS animals with or without heat shock were
anaesthetized in 20 mM sodium azide in M9 buffer, mounted
on an agarose pad with cover slip and examined with a stand-
ard fluorescent microscope or confocal microscope (Nikon
H600L, Japan).
Lifespan analysis
Animals were placed on NGM plates (n ¼ 20) and replated
daily, and the number of live animals was counted. Immobile,
shrunken animals were considered to have died.
Western blot analysis
Animals were lysed in RIPA buffer with sonication. After
removing undissolved debris by centrifugation, protein concen-
trations of the lysates were determined by bicinchoninic acid
assay. Equal amounts of protein were subjected to NuPAGE
Bis–Tris (Invitrogen); transferred onto nitrocellulose mem-
brane (Whatman, Germany) and detected by western blotting
with anti-GFP (Abcam, USA), anti-FUS (Santa Cruz Biotech-
nology, USA) or anti-tubulin (Abcam) antibodies. For analysis
of the solubility of FUS proteins, RIPA lysates were centrifuged
at 100 000g for 30 min at 48C. The pellets were resuspended in
urea buffer (7 M urea, 2 M thiourea, 4% CHAPS, 30 mM Tris–
HCl, pH 8.5), sonicated and centrifuged at 100 000g for
30 min at room temperature (10).
Statistical analysis
For statistical analysis, the unpaired Student’s t-tests and ana-
lysis of variance were performed with SigmaPlot version 11.0.
SUPPLEMENTARY MATERIAL
Supplementary Material is available at HMG online.
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